Two Israeli Biomed Firms Nab FDA Approval For Separate COVID-19 Trials In US
Both RedHill BioPharma and Pluristem Therapeutics said they were given the green light for their imminent studies treating serious SARS CoV2 infections.
May 10, 2020
In New Study, Israeli Biopharma Firm’s Drug For Crohn’s Disease Shows Positive Results
Results show RHB-104, developed by Redhill Biopharma, could lead to a 'paradigm shift' in the treatment of the gastrointestinal disease.
July 31, 2018
